904724

Pomalidomide-PEG₂-butyl iodide

≥95%

• Synonym(s): Crosslinker–E3 Ligase ligand conjugate, Pomalidomide-2-2-6-I, N-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-2-(2-((6-iodohexyl)oxy)ethoxy)acetamide, Protein degrader building block for PROTAC^® research, Template for synthesis of targeted protein degrader
• Empirical Formula (Hill Notation): C₂₃H₂₈IN₃O₇
• CAS Number: 1835705-72-0
• Molecular Weight: 585.39
• MDL number: MFCD32173806
• UNSPSC Code: 12352101
• NACRES: NA.22

Properties

• ligand: pomalidomide
• assay: ≥95%
• form: powder or crystals
• reaction suitability: reactivity: sulfuryl reactive, reagent type: ligand-linker conjugate
• functional group: alkyl halide
• storage temp.: 2-8°C
• SMILES string: ICCCCCCOCCOCC(NC1=CC=CC2=C1C(N(C3CCC(NC3=O)=O)C2=O)=O)=O
• InChI: 1S/C23H28IN3O7/c24-10-3-1-2-4-11-33-12-13-34-14-19(29)25-16-7-5-6-15-20(16)23(32)27(22(15)31)17-8-9-18(28)26-21(17)30/h5-7,17H,1-4,8-14H2,(H,25,29)(H,26,28,30)
• InChI key: NYFZCMZZMDMBEB-UHFFFAOYSA-N

Description

Application

Protein degrader builiding block Pomalidomide-PEG₂-butyl Iodide enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology. This conjugate contains a Cereblon (CRBN)-recruiting ligand, a linker with both hydrophobic and hydrophilic moieties, and a pendant iodoalkane for reactivity with a nucleophilic group on a target ligand. Because even slight alterations in ligands and crosslinkers can affect ternary complex formation between the target, E3 ligase, and PROTAC, many analogs are prepared to screen for optimal target degradation. When used with other protein degrader building blocks with a pendant iodo group, parallel synthesis can be used to more quickly generate PROTAC libraries that feature variation in crosslinker length, composition, and E3 ligase ligand.

Other Notes

Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation

Portal: Building PROTAC^® Degraders for Targeted Protein Degradation

Targeting the C481S Ibrutinib-Resistance Mutation in Bruton′s Tyrosine Kinase Using PROTAC-Mediated Degradation

Modular PROTAC Design for the Degradation of Oncogenic BCR-?ABL

Targeted Protein Degradation by Small Molecules

Small-Molecule PROTACS: New Approaches to Protein Degradation

Targeted Protein Degradation: from Chemical Biology to Drug Discovery

Impact of linker length on the activity of PROTACs

Legal Information

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

Safety Information

• Storage Class: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable